145 related articles for article (PubMed ID: 36473621)
1. DHCR7 promotes tumorigenesis via activating PI3K/AKT/mTOR signalling pathway in bladder cancer.
Li Y; Zhou Y; Huang M; Wang Z; Liu D; Liu J; Fu X; Yang S; Shan S; Yang L; Guo Y; Ren P; Chen P; Zeng G; Guo Y; Wang X; DiSanto ME; Zhang X
Cell Signal; 2023 Feb; 102():110553. PubMed ID: 36473621
[TBL] [Abstract][Full Text] [Related]
2. FOXK1 promotes malignant progression of breast cancer by activating PI3K/AKT/mTOR signaling pathway.
Li ZQ; Qu M; Wan HX; Wang H; Deng Q; Zhang Y
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9978-9987. PubMed ID: 31799667
[TBL] [Abstract][Full Text] [Related]
3. Decreased TRPM7 inhibits activities and induces apoptosis of bladder cancer cells via ERK1/2 pathway.
Cao R; Meng Z; Liu T; Wang G; Qian G; Cao T; Guan X; Dan H; Xiao Y; Wang X
Oncotarget; 2016 Nov; 7(45):72941-72960. PubMed ID: 27662662
[TBL] [Abstract][Full Text] [Related]
4. HYOU1 promotes cell proliferation, migration, and invasion via the PI3K/AKT/FOXO1 feedback loop in bladder cancer.
Wang W; Jiang X; Xia F; Chen X; Li G; Liu L; Xu Q; Zhu M; Chen C
Mol Biol Rep; 2023 Jan; 50(1):453-464. PubMed ID: 36348197
[TBL] [Abstract][Full Text] [Related]
5. CircHGS enhances the progression of bladder cancer by regulating the miR-513a-5p/VEGFC axis and activating the AKT/mTOR signaling pathway.
Zhu Y; Zuo L; Xiong H; Li S; Chen R; Liu H
Cell Cycle; 2023 Apr; 22(8):919-938. PubMed ID: 36617735
[TBL] [Abstract][Full Text] [Related]
6. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
7. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
[TBL] [Abstract][Full Text] [Related]
8. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
9. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
10. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway.
Lin Q; Chen H; Zhang M; Xiong H; Jiang Q
Biomed Pharmacother; 2019 Jul; 115():108939. PubMed ID: 31079003
[TBL] [Abstract][Full Text] [Related]
11. Metformin exerts an antitumor effect by inhibiting bladder cancer cell migration and growth, and promoting apoptosis through the PI3K/AKT/mTOR pathway.
Shen Z; Xue D; Wang K; Zhang F; Shi J; Jia B; Yang D; Zhang Q; Zhang S; Jiang H; Luo D; Li X; Zhong Q; Zhang J; Peng Z; Han Y; Sima C; He X; Hao L
BMC Urol; 2022 May; 22(1):79. PubMed ID: 35610639
[TBL] [Abstract][Full Text] [Related]
12. DTL Is a Prognostic Biomarker and Promotes Bladder Cancer Progression through Regulating the AKT/mTOR axis.
Luo Y; He Z; Liu W; Zhou F; Liu T; Wang G
Oxid Med Cell Longev; 2022; 2022():3369858. PubMed ID: 35103094
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway.
Liang Z; Wang X; Xu X; Xie B; Ji A; Meng S; Li S; Zhu Y; Wu J; Hu Z; Lin Y; Zheng X; Xie L; Liu B
Mol Cancer; 2017 May; 16(1):96. PubMed ID: 28549468
[TBL] [Abstract][Full Text] [Related]
14. Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1.
Zhao J; Shi L; Zeng S; Ma C; Xu W; Zhang Z; Liu Q; Zhang P; Sun Y; Xu C
Urol Oncol; 2018 Jun; 36(6):311.e1-311.e13. PubMed ID: 29602637
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
16. UBE2T promotes proliferation, invasion and glycolysis of breast cancer cells by regualting the PI3K/AKT signaling pathway.
Qiao L; Dong C; Ma B
J Recept Signal Transduct Res; 2022 Apr; 42(2):151-159. PubMed ID: 33435787
[TBL] [Abstract][Full Text] [Related]
17. BHLHE41 inhibits bladder cancer progression via regulation of PYCR1 stability and thus inactivating PI3K/AKT signaling pathway.
Xiao S; Chen J; Wei Y; Song W
Eur J Med Res; 2024 May; 29(1):302. PubMed ID: 38811952
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
[TBL] [Abstract][Full Text] [Related]
19. Pyrroline-5-Carboxylate Reductase-2 Promotes Colorectal Cancer Progression via Activating PI3K/AKT/mTOR Pathway.
Yin F; Huang X; Xuan Y
Dis Markers; 2021; 2021():9950663. PubMed ID: 34512817
[TBL] [Abstract][Full Text] [Related]
20. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
